

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/379502565>

# INFLUENCE OF ANTIRETROVIRAL THERAPY ON MATERNAL EOSINOPHIL LEVELS DURING PREGNANCY: A REVIEW

Article in International Journal of Innovative and Applied Research · April 2024

DOI: 10.58538/IJIAR/2094

---

CITATIONS

0

---

READ

1

2 authors:



**Emmanuel Ifeanyi Obeagu**  
Kampala International University (KIU)

1,601 PUBLICATIONS 20,695 CITATIONS

SEE PROFILE



**Getrude Uzoma Obeagu**  
Kampala International University (KIU)

515 PUBLICATIONS 9,302 CITATIONS

SEE PROFILE



Journal home page: <http://www.journalijar.com>

INTERNATIONAL JOURNAL  
OF INNOVATIVE AND APPLIED RESEARCH

## REVIEW ARTICLE

Article DOI: 10.58538/IJAR/2094

DOI URL: <http://dx.doi.org/10.58538/IJAR/2094>

### INFLUENCE OF ANTIRETROVIRAL THERAPY ON MATERNAL EOSINOPHIL LEVELS DURING PREGNANCY: A REVIEW

Emmanuel Ifeanyi Obeagu<sup>1</sup> and Getrude Uzoma Obeagu<sup>2</sup>

1. Department of Medical Laboratory Science, Kampala International University, Ishaka, Uganda.
2. School of Nursing Science, Kampala International University, Ishaka, Uganda.

#### Manuscript Info

#### Manuscript History

Received: 28 February 2024  
Final Accepted: 29 March 2024  
Published: March 2024

#### Keywords:

Antiretroviral Therapy, Maternal Health, Pregnancy, Eosinophils, Immune Response, HIV/AIDS, Inflammation, Immunomodulation, Pediatrics, Public Health

#### Abstract

Antiretroviral therapy (ART) has revolutionized the management of HIV infection, significantly reducing morbidity and mortality in individuals living with the virus. However, the influence of ART on maternal eosinophil levels during pregnancy remains a topic of interest and debate. This review explores the current understanding of how ART affects eosinophil levels in pregnant women living with HIV, considering both the potential mechanisms underlying these changes and their clinical implications. Keywords such as HIV, antiretroviral therapy, pregnancy, eosinophils, immune response, and maternal health are utilized to delve into relevant literature and provide insights into this complex interaction. Understanding the impact of ART on maternal eosinophil levels can contribute to optimizing the management of HIV during pregnancy, ensuring maternal health, and promoting favorable pregnancy outcomes.

\*Corresponding Author:- Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Ishaka, Uganda.

#### Introduction:-

Antiretroviral therapy (ART) has transformed the landscape of HIV/AIDS management, offering individuals living with HIV the opportunity for prolonged and improved quality of life. In pregnant women living with HIV, ART plays a crucial role not only in controlling the viral load to prevent vertical transmission but also in preserving maternal health. However, as the use of ART becomes more widespread in this population, there is growing interest in understanding its potential effects on various aspects of maternal physiology, including immune function. Among these considerations, the influence of ART on maternal eosinophil levels during pregnancy has garnered attention due to its potential implications for maternal health and pregnancy outcomes. Eosinophils are multifunctional granulocytes involved in the immune response against parasitic infections, allergic reactions, and tissue repair. Beyond these roles, eosinophils have also been implicated in modulating inflammatory responses and maintaining immune homeostasis during pregnancy. Given the immunomodulatory effects of ART, there is speculation that ART may impact eosinophil levels in pregnant women living with HIV. However, the specific mechanisms underlying these potential changes remain unclear, prompting further investigation into the interaction between ART and maternal eosinophils.<sup>1-25</sup>

Understanding the influence of ART on maternal eosinophil levels is not only of scientific interest but also holds clinical relevance. Eosinophils have been implicated in various pregnancy-related conditions, including

preeclampsia, gestational diabetes, and preterm birth. Therefore, any alterations in eosinophil levels induced by ART could potentially influence the risk of developing these complications. Additionally, since eosinophils play a role in modulating immune responses, changes in their levels may impact the maternal immune milieu and, consequently, fetal development and pregnancy outcomes.<sup>26-35</sup>

Therefore, a comprehensive review of existing literature is warranted to elucidate the relationship between ART and maternal eosinophil levels during pregnancy. By synthesizing available evidence and identifying gaps in knowledge, this review aims to provide insights into this complex interaction, guiding future research directions and informing clinical practice in the management of HIV in pregnant women.

### **Antiretroviral Therapy and Maternal Health**

Antiretroviral therapy (ART) has revolutionized the management of HIV/AIDS, significantly improving both the quantity and quality of life for individuals living with the virus. In pregnant women living with HIV, ART plays a crucial role not only in preventing vertical transmission to the fetus but also in preserving maternal health throughout pregnancy and beyond. This section explores the profound impact of ART on maternal health, highlighting its various benefits and considerations. First and foremost, ART effectively suppresses viral replication, thereby reducing maternal viral load to undetectable levels or significantly lower levels. By maintaining viral suppression, ART helps prevent the progression of HIV disease in pregnant women, reducing the risk of AIDS-related illnesses and improving overall maternal well-being. Moreover, effective viral suppression through ART contributes to the restoration and preservation of immune function, enhancing the ability of pregnant women to combat opportunistic infections and other HIV-related complications.<sup>36-60</sup>

In addition to its direct effects on HIV control, ART also plays a pivotal role in preventing mother-to-child transmission (PMTCT) of HIV. By initiating ART early in pregnancy, ideally before conception or as soon as HIV infection is diagnosed, pregnant women can achieve maximal viral suppression, minimizing the risk of transmitting the virus to their infants. Through PMTCT interventions, including ART, maternal viral suppression, elective cesarean delivery when indicated, and avoidance of breastfeeding in certain settings, the risk of vertical transmission can be reduced to less than 1%, ensuring the birth of HIV-negative infants to HIV-positive mothers. Furthermore, ART has been associated with improved maternal outcomes during pregnancy, labor, and delivery. Studies have shown that pregnant women receiving ART have lower rates of HIV-related complications such as opportunistic infections, HIV-associated malignancies, and AIDS-defining illnesses. Additionally, ART has been linked to reduced rates of adverse pregnancy outcomes, including preterm birth, low birth weight, and perinatal mortality. By optimizing maternal health and pregnancy outcomes, ART contributes to the overall well-being of both mothers and their infants. Despite the undeniable benefits of ART in promoting maternal health during pregnancy, its use may also pose certain challenges and considerations. Adherence to ART regimens is critical to achieving and maintaining viral suppression, yet barriers such as pill burden, side effects, stigma, and psychosocial factors can impact adherence rates. Moreover, the potential long-term effects of ART on maternal health, including metabolic complications, cardiovascular disease, and bone health, warrant ongoing monitoring and research.<sup>61-95</sup>

### **Eosinophils in Pregnancy**

Eosinophils, a type of white blood cell, play a crucial role in immune responses, particularly in combating parasitic infections and modulating allergic reactions. During pregnancy, eosinophils also contribute to immune regulation and maintenance of maternal-fetal tolerance. Understanding the dynamics of eosinophils in pregnancy is essential for comprehending their role in maternal health and pregnancy outcomes. Throughout gestation, eosinophil levels fluctuate under the influence of hormonal and immunological changes. In the early stages of pregnancy, eosinophil counts may decrease due to alterations in hormonal milieu, including elevated levels of progesterone, which can suppress eosinophil production. However, as pregnancy progresses, eosinophil counts tend to increase, reaching peak levels in the third trimester. These changes are thought to be partly mediated by cytokines and chemokines produced by the placenta and fetal tissues.<sup>96-105</sup>

Eosinophils in pregnancy play diverse roles beyond their traditional functions in immunity. They contribute to the regulation of inflammation and tissue remodeling, processes crucial for successful implantation, placental development, and fetal growth. Moreover, eosinophils exhibit immunomodulatory properties that help maintain maternal-fetal tolerance, preventing rejection of the semi-allogeneic fetus. Dysregulation of eosinophil activity during pregnancy has been implicated in various pregnancy complications, including preeclampsia, preterm birth, and gestational diabetes, highlighting the importance of their balanced function. In addition to their physiological

roles, eosinophils may also be influenced by external factors, including medications such as antiretroviral therapy (ART) used in the management of HIV during pregnancy. While the specific effects of ART on eosinophil levels in pregnant women living with HIV remain understudied, it is plausible that ART-mediated immune modulation could impact eosinophil dynamics during pregnancy. Understanding the interplay between ART and eosinophils is crucial for optimizing maternal health outcomes in HIV-infected pregnant women and ensuring the well-being of their offspring.<sup>106-115</sup>

### **Impact of ART on Maternal Eosinophil Levels**

Antiretroviral therapy (ART) has revolutionized the management of HIV/AIDS, significantly improving the health and well-being of individuals living with the virus. However, the impact of ART on maternal eosinophil levels during pregnancy remains an area of interest and investigation. Understanding how ART influences eosinophil levels is essential for optimizing maternal health outcomes in HIV-infected pregnant women. Some evidence suggests that certain antiretroviral medications, particularly nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs), may affect eosinophil counts. For example, studies have reported decreases in eosinophil levels following initiation of ART, particularly with regimens containing specific NRTIs such as zidovudine (AZT) or stavudine (d4T). Conversely, other studies have observed increases in eosinophil counts with certain ART regimens or specific drugs within these classes. The mechanisms underlying these effects are not fully understood but may involve direct effects of ART on hematopoiesis or immune modulation.<sup>116-144</sup>

In the context of pregnancy, the impact of ART on maternal eosinophil levels appears to be less well studied. Limited evidence suggests that pregnant women living with HIV may experience changes in eosinophil counts following initiation of ART, similar to those observed in non-pregnant individuals. However, the specific effects of ART on eosinophil dynamics during pregnancy remain unclear. Given the immunomodulatory effects of ART and the importance of eosinophils in immune regulation during pregnancy, further research is needed to elucidate this relationship. Understanding the impact of ART on maternal eosinophil levels is clinically significant for several reasons. Eosinophils play a role in immune regulation and inflammation, processes that are crucial for maternal-fetal tolerance and pregnancy outcomes. Dysregulation of eosinophil levels during pregnancy has been implicated in various pregnancy complications, including preeclampsia and preterm birth. Therefore, any alterations in eosinophil levels induced by ART could potentially influence the risk of developing these complications in pregnant women living with HIV.<sup>145-164</sup>

### **Clinical Implications and Future Directions**

The impact of antiretroviral therapy (ART) on maternal eosinophil levels during pregnancy carries several clinical implications and warrants further investigation to guide clinical practice and improve maternal and fetal outcomes in HIV-infected women. Understanding these implications and identifying future research directions is crucial for optimizing ART regimens and ensuring the safety and efficacy of treatment in this vulnerable population. Firstly, elucidating the specific effects of ART on eosinophil dynamics during pregnancy is essential for risk stratification and personalized management of HIV-infected pregnant women. If certain ART regimens or drugs within these classes are found to significantly alter eosinophil levels, clinicians may need to consider alternative treatment options to minimize the risk of adverse pregnancy outcomes associated with eosinophil dysregulation. Additionally, monitoring eosinophil levels during pregnancy may provide valuable prognostic information and help identify women at higher risk of developing complications such as preeclampsia or preterm birth.<sup>165-171</sup>

Furthermore, investigating the mechanisms underlying ART-induced changes in eosinophil levels can offer insights into the immunomodulatory effects of these medications and their broader impact on maternal immune function during pregnancy.<sup>172</sup> Understanding how ART influences eosinophil production, activation, and function may shed light on the complex interplay between viral suppression, immune regulation, and pregnancy outcomes in HIV-infected women. This knowledge could inform the development of novel therapeutic strategies aimed at modulating eosinophil activity to improve maternal and fetal health outcomes in this population. Moreover, exploring the association between ART-induced alterations in eosinophil levels and specific pregnancy complications, such as preeclampsia or preterm birth, can provide valuable insights into the pathophysiology of these conditions and identify potential biomarkers for risk stratification and early detection. Identifying biomarkers associated with adverse pregnancy outcomes in HIV-infected women may facilitate targeted interventions and closer monitoring of at-risk individuals, ultimately reducing the burden of maternal and neonatal morbidity and mortality in this population.<sup>172-</sup>

**Conclusion:-**

The impact of antiretroviral therapy (ART) on maternal eosinophil levels during pregnancy represents a complex and understudied aspect of HIV/AIDS management in pregnant women. While evidence regarding the specific effects of ART on eosinophil dynamics during pregnancy remains limited, understanding this relationship carries significant clinical implications for optimizing ART regimens and improving maternal and fetal outcomes. Despite the lack of comprehensive data, it is clear that eosinophils play a crucial role in immune regulation and inflammation during pregnancy, with dysregulation implicated in various pregnancy complications. Therefore, elucidating how ART influences eosinophil levels and function is essential for identifying potential risks and mitigating adverse outcomes in HIV-infected pregnant women.

**References:-**

1. Forsythe SS, McGreevey W, Whiteside A, Shah M, Cohen J, Hecht R, Bollinger LA, Kinghorn A. Twenty years of antiretroviral therapy for people living with HIV: global costs, health achievements, economic benefits. *Health affairs*. 2019;38(7):1163-1172.
2. Antela A, Rivero A, Llibre JM, Moreno S. Redefining therapeutic success in HIV patients: an expert view. *Journal of Antimicrobial Chemotherapy*. 2021;76(10):2501-2518.
3. Ndashimye E, Arts EJ. The urgent need for more potent antiretroviral therapy in low-income countries to achieve UNAIDS 90-90-90 and complete eradication of AIDS by 2030. *Infectious Diseases of Poverty*. 2019;8(04):67-74.
4. Lazarus JV, Wohl DA, Cascio M, Guaraldi G, Rockstroh J, Hodson M, Richman B, Brown G, Anderson J, Fuster-RuizdeApodaca MJ. Long-term success for people living with HIV: a framework to guide practice. *HIV medicine*. 2023; 24:8-19.
5. Stangl AL, Wamai N, Mermin J, Awor AC, Bunnell RE. Trends and predictors of quality of life among HIV-infected adults taking highly active antiretroviral therapy in rural Uganda. *AIDS care*. 2007;19(5):626-636.
6. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. *Journal home page*: [http://www.journalijiar.com](http://www.journalijiar.com;);12(01).
7. Obeagu EI, Obeagu GU. Studies on platelets diagnostic indexes in patients with acute myeloid leukaemia in Uganda. *Int. J. Curr. Res. Med. Sci*. 2023;9(1):24-27.
8. Obeagu EI, Okechukwu PU, Alum EU, Obeagu GU, Opoku D, Scott GY, Amekpor F. Platelets as actors in inflammation and immunity: A fulcrum in immunity. *Int. J. Adv. Res. Biol. Sci*. 2023;10(3):81-89.
9. Obeagu EI, Mbabazi A, Obeagu GU, Muhimbura E, Igwe MC, Owunna TA, Okafor CJ, Jakheng SP. Evaluation of Platelets and Some Inflammation Markers of Patients with Acute Myeloid Leukaemia In A Tertiary Hospital In Uganda. *Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035*. 2022;2(3):78-84.
10. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. *Journal home page*: [http://www.journalijiar.com](http://www.journalijiar.com;);12(01).
11. Ifeanyi OE, Favour AA, Prayer NN. Updates on Human Immunodeficiency Virus and Platelets. *Int. J. Adv. Res. Biol. Sci*. 2020;7(6):1-7.
12. Obeagu EI, Muhimbura E, Kagenderezo BP, Nakyeyune S, Obeagu GU. An Insight of Interleukin-6 and Fibrinogen: In Regulating the Immune System. *J Biomed Sci*. 2022;11(10):83.
13. Okoroiwu IL, Obeagu EI, Vivian Egwim V. Assessment of White Blood Cell Count and Platelet Count in Women on Hormonal Contraceptives in Owerri, Imo State, Nigeria. *J Res Med Dent Sci*. 2021;9(12):498-501.
14. Obeagu EI, Okoroiwu IL, Obeagu GU. Relationship between Thrombopoietin and Interleukin 3: A Review. *Int J Curr Res Chem Pharm. Sci*. 2022;9(1):7-13.
15. Ukonu UC, Nwosu DC, Okoroiwu LI, Dike-Ndudim JN, Ukonu GO, Obeagu EI. Evaluation of Alloantibodies to human platelet antigen and Leucocyte antigen class 1 in Multitransfused patients in Owerri, Imo state. *Int. J. Curr. Res. Med. Sci*. 2023;9(1):38-44.
16. Obeagu EI. Gestational Thrombocytopenia. *J Gynecol Women's Health*. 2023;25(3):556163.
17. Okoroiwu IL, Obeagu EI, Obeagu GU. Determination of clot retraction in pregnant women attending antenatal clinic in federal medical centre Owerri, Nigeria. *Madonna University Journal of Medicine and Health Sciences*. 2022;2(2):91-97.
18. Ezimah AC, Obeagu EI, Asur A, Ezimah UA, Ezimah CO. Absolute platelet count in adult patients with musculoskeletal pain: Current perspectives. *Int. J. Curr. Res. Med. Sci*. 2016;2(2):30-7.
19. Obeagu EI, Ogunnaya FU. Pregnancy-induced Haematological Changes: A Key to Maternal and Child Health. *European Journal of Biomedical*. 2023;10(8):42-43.

20. Obeagu EI, Chikelu IM, Obarezi TN, Ogbuabor BN, Anaebo QB. Haematological effects of fluted pumpkin (*Telfairia occidentalis*) leaves in rats. *International Journal of Life Sciences Biotechnology and Pharma Research*. 2014;3(1):172-182.
21. Obeagu EI, Agreen FC. Anaemia among pregnant women: A review of African pregnant teenagers. *J Pub Health Nutri*. 2023; 6 (1). 2023;138.links/63da799664fc860638054562/Anaemia-among-pregnant-women-A-review-of-African-pregnant-teenagers.pdf.
22. Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in the anaemias of pregnancy: a review. *Int J Curr Res Chem Pharm Sci*. 2016;3(3):10-8.links/5710fae108ae846f4ef05afb/ERYTHROPOIETIN-IN-THE-ANAEMIAS-OF-PREGNANCY-A-REVIEW.pdf.
23. Obeagu EI, Adepoju OJ, Okafor CJ, Obeagu GU, Ibekwe AM, Okpala PU, Agu CC. Assessment of Haematological Changes in Pregnant Women of Ido, Ondo State, Nigeria. *J Res Med Dent Sci*. 2021 Apr;9(4):145-8.links/608a6728a6fdccaebdf52d94/Assessment-of-Haematological-Changes-in-Pregnant-Women-of-Ido-Ondo.pdf.
24. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. *International Research in Medical and Health Sciences*. 2023 Jun 10;6(2):10-3.http://irmhs.com/index.php/irmhs/article/view/111.
25. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. *J Pub Health Nutri*. 2022; 5 (8). 2022;137.links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.
26. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):120-127.
27. Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among youths: A review of Africa perspective. *Madonna University journal of Medicine and Health Sciences*. 2023;3(1):13-18.https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93.
28. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023 ;3(1):7-12.https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.
29. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. *J Pub Health Nutri*. 2023; 6 (2). 2023; 141:1-2.links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.
30. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
31. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. *Int J Curr Res Med Sci*. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
32. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. *Int. J. Curr. Res. Med. Sci*. 2023;9(2): 1-5.DOI: 10.22192/ijcrms.2023.09.02.001
33. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. *J Pub Health Nutri*. 2022; 5 (6). 2022;129.links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
34. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.
35. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
36. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. *Journal of Pharmaceutical Research International*. 2020;32(22):101-119.
37. Obeagu EI, Eze VU, Alaebob EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. *J BioInnovation*. 2016; 5:464-

- 471.links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.
38. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. *International Journal of Current Microbiology and Applied Sciences*. 2015;4(4):911-916.[https://www.academia.edu/download/38320140/Obeagu\\_Emmanuel\\_Ifeanyi\\_and\\_Obeagu\\_Getrude\\_Uzoma2.EMMA1.pdf](https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).
39. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. *Int. J. Adv. Res. Biol. Sci.* 2016;3(10): 55-65.DOI: 10.22192/ijarbs.2016.03.10.009
40. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci.* 2017;12(4):70-75.links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
41. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):110-119.
42. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. *J. Bio. Innov.* 2016;5(1):24-30.links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
43. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. *J Pub Health Nutri.* 2022; 5 (6). 2022;130.links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf.
44. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. *Int J Curr Res Aca Rev.* 2015; 3:139-144.[https://www.academia.edu/download/38320159/Obeagu\\_Emmanuel\\_Ifeanyi3\\_et\\_al.IJCRAR.pdf](https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3_et_al.IJCRAR.pdf).
45. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. *Ann Clin Lab Res.* 2018;6(1):1-4.links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
46. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. *Int. J. Curr. Res. Med. Sci.* 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
47. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. *Health Science Reports.* 2023;6(8):e1450.
48. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. *J Pub Health Nutri.* 2023; 6 (1). 2023;139.links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
49. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. *Madonna University journal of Medicine and Health Sciences.* 2022;2(3):128-134.<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86>.
50. Walter O, Anaebo QB, Obeagu EI, Okoroiew IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. *Journal of Pharmaceutical Research International.* 2022:29-34.
51. Obeagu EI, Obeagu GU, Chukwueze CM, Ikpenwa JN, Ramos GF. Evaluation of Protein C, Protein S and Fibrinogen of Pregnant Women with Malaria in Owerri Metropolis. *Madonna University journal of Medicine and Health Sciences.* 2022;2(2):1-9.
52. Obeagu EI, Ikpenwa JN, Chukwueze CM, Obeagu GU. Evaluation of protein C, protein S and fibrinogen of pregnant women in Owerri Metropolis. *Madonna University Journal of Medicine and Health Sciences.* 2022;2(1):292-8.<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/57>.

53. Obeagu EI, Obeagu GU, Adepoju OJ. Evaluation of haematological parameters of pregnant women based on age groups in Olorunsogo road area of Ido, Ondo state. *J. Bio. Innov* 11 (3). 2022:936-41.
54. Obeagu EI. An update on utilization of antenatal care among pregnant Women in Nigeria. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2022;9(9):21-6.DOI: 10.22192/ijcrps.2022.09.09.003
55. Okoroiwu IL, Obeagu EI, Obeagu GU. Determination of clot retraction in pregnant women attending antenatal clinic in federal medical centre Owerri, Nigeria. *Madonna University Journal of Medicine and Health Sciences.* 2022;2(2):91-7.<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/67>.
56. Obeagu EI, Hassan AO, Adepoju OJ, Obeagu GU, Okafor CJ. Evaluation of Changes in Haematological Parameters of Pregnant Women Based on Gestational Age at Olorunsogo Road Area of Ido, Ondo State, Nigeria. *Journal of Research in Medical and Dental Science.* 2021;9(12):462-.[links/61b1e32f0c4bfb675178bfa7/Evaluation-of-Changes-in-Haematological-Parameters-of-Pregnant-Women-Based-on-Gestational-Age-at-Olorunsogo-Road-Area-of-Ido-Ondo-State-Nigeria.pdf](https://www.researchgate.net/publication/358117867/Evaluation-of-Changes-in-Haematological-Parameters-of-Pregnant-Women-Based-on-Gestational-Age-at-Olorunsogo-Road-Area-of-Ido-Ondo-State-Nigeria).
57. Anyiam AF, Obeagu EI, Obi E, Omosigho PO, Irondi EA, Arinze-Anyiam OC, Asiyah MK. ABO blood groups and gestational diabetes among pregnant women attending University of Ilorin Teaching Hospital, Kwara State, Nigeria. *International Journal of Research and Reports in Hematology.* 2022 Jun 21;5(2):113-121.
58. Obeagu EI. Gestational Thrombocytopaenia. *J Gynecol Women's Health.* 2023;25(3):556163.[links/64b01aa88de7ed28ba95fccb/Gestational-Thrombocytopaenia.pdf](https://www.researchgate.net/publication/364601aa88de7ed28ba95fccb/Gestational-Thrombocytopaenia.pdf).
59. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *South Asian Journal of Research in Microbiology.* 2022 Aug 9;13(2):26-31.
60. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International.* 2021 Feb 23;33(4):10-9.
61. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. *Journal of Pharmaceutical Research International.* 2020;32(24):9-18.
62. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. *J Pub Health Nutri.* 2022; 5 (8). 2022;137.[links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf](https://www.researchgate.net/publication/36317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf).
63. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. *Int. J. Adv. Res. Biol. Sci.* 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 [links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf](https://www.researchgate.net/publication/36516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf)
64. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. *Int. J. Adv. Res. Biol. Sci.* 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 [links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf](https://www.researchgate.net/publication/36516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf).
65. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfecting with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 [https://www.academia.edu/download/54317126/Haematological\\_indices\\_of\\_malaria\\_patients\\_coinfected\\_with\\_HIV.pdf](https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf)
66. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *South Asian Journal of Research in Microbiology.* 2022;13(2):26-31.
67. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. *Asian Journal of Dental and Health Sciences.* 2023;3(2):7-14.<http://ajdhs.com/index.php/journal/article/view/39>.
68. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in Owerri, Nigeria. *J Clin Commun Med.* 2020;2(3):180-183.DOI:DOI: 10.32474/JCCM.2020.02.000137links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-



- Immunosorbent-Assay-EIISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
69. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. *Journal of Pharmaceutical Research International*. 2021;33(47A):78-84.
  70. Emmanuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. *Asian Journal of Pregnancy and Childbirth*. 2023 Jul 29;6(1):203-211.<http://research.sdpublishers.net/id/eprint/2819/>.
  71. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Stephen PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. *Asian Journal of Research in Infectious Diseases*. 2022;10(4):1-7.
  72. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. *Journal of Pharmaceutical Research International*. 2021;33(57A):360-368.
  73. Igwe MC, Obeagu EI, Ogbuabor AO. ANALYSIS OF THE FACTORS AND PREDICTORS OF ADHERENCE TO HEALTHCARE OF PEOPLE LIVING WITH HIV/AIDS IN TERTIARY HEALTH INSTITUTIONS IN ENUGU STATE. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):42-57.<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75>.
  74. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):6-15.<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69>
  75. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. *European Journal of Pharmaceutical and Medical Research*, 2023;10(8): 564-568
  76. Obeagu EI, Abdirahman BF, Bunu UO, Obeagu GU. Obstetrics characteristics that effect the newborn outcomes. *Int. J. Adv. Res. Biol. Sci*. 2023;10(3):134-43.DOI: 10.22192/ijarbs.2023.10.03.016
  77. Obeagu EI, Ogunnaya FU. PREGNANCYINDUCED HAEMATOLOGICAL CHANGES: A KEY TO MARTERNAL AND CHILD HEALTH. *European Journal of Biomedical*. 2023;10(8):42-3.[links/64c890bddb38b20d6dad2c5c/PREGNANCY-INDUCED-HAEMATOLOGICAL-CHANGES-A-KEY-TO-MARTERNAL-AND-CHILD-HEALTH.pdf](https://doi.org/10.22192/ijarbs.2023.10.03.016).
  78. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-9.
  79. Okamgba OC, Nwosu DC, Nwobodo EI, Agu GC, Ozims SJ, Obeagu EI, Ibanga IE, Obioma-Elemba IE, Ihekaire DE, Obasi CC, Amah HC. Iron Status of Pregnant and Post-Partum Women with Malaria Parasitaemia in Aba Abia State, Nigeria. *Annals of Clinical and Laboratory Research*. 2017;5(4):206.[links/5ea97df145851592d6a8acf2/Iron-Status-of-Pregnant-and-Post-Partum-Women-with-Malaria-Parasitaemia-in-Aba-Abia-State-Nigeria.pdf](https://doi.org/10.22192/ijarbs.2023.10.03.016).
  80. Eze RI, Obeagu EI, Edet FN. Frequency of Rh Antigen C And c among pregnant women in Sub-Urban area in Eastern Nigeria. *Madonna Uni J Med Health Sci*. 2021;1(1):19-30.
  81. Obeagu EI, Ofodile AC, Okwuanaso CB. A review of urinary tract infections in pregnant women: Risks factors. *J Pub Health Nutri*. 2023; 6 (1). 2023;137:26-35.[links/63c3a9116fe15d6a571e8bba/A-review-of-urinary-tract-infections-in-pregnant-women-Risks-factors.pdf](https://doi.org/10.22192/ijarbs.2023.10.03.016).
  82. Obeagu EI, Obeagu GU, Musiimenta E. Post partum haemorrhage among pregnant women: Update on risks factors. *Int. J. Curr. Res. Med. Sci*. 2023;9(2):14-7.DOI: 10.22192/ijcrms.2023.09.02.003
  83. Obeagu EI, Obeagu GU, Ogunnaya FU. Deep vein thrombosis in pregnancy: A review of prevalence and risk factors. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2023;10(8):14-21.DOI: 10.22192/ijcreps.2023.10.08.002
  84. Jakheng SP, Obeagu EI, Jakheng EW, Uwakwe OS, Eze GC, Obeagu GU, Vidya S, Kumar S. Occurrence of Chlamydial Infection Based on Clinical Symptoms and Clinical History among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *International Journal of Research and Reports in Gynaecology*. 2022;5(3):98-105.

85. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of some haematological parameters in malaria infected pregnant women in Imo state Nigeria. *Int. J. Curr. Res. Biol. Med.* 2018;3(9):1-4.DOI: 10.22192/ijcrbm.2018.03.09.001
86. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatanunya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETROVIRAL THERAPY. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2015; 4(3): 153-160. [links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf](https://www.wjpps.com/links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf).
87. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. *Int. J. Curr. Res. Biosci. Plant Biol.* 2015;2(4):45-49.
88. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2019;6(12):45-8.DOI: 10.22192/ijcrps.2019.06.12.004 [links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf](https://www.ijcrps.com/links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf).
89. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. *Int. J. Curr. Res. Med. Sci.* 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 [links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf](https://www.ijcrms.com/links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf).
90. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2016;2(4):29-33.[links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf](https://www.ijcrms.com/links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf).
91. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. *Int. J. Curr. Microbiol. App. Sci.* 2015;4(4):906-910.[https://www.academia.edu/download/38320134/Obeagu\\_Emmanuel\\_Ifeanyi\\_and\\_Obeagu\\_Getrude\\_Uzoma.EMMA2.pdf](https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma.EMMA2.pdf).
92. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. *Int. J. Curr. Res. Biol. Med.* 2016;1(2):1-5.
93. Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailing HIV/AIDS Spread: Impact of Religious Leaders. *Newport International Journal of Research in Medical Sciences (NIJRMS)*. 2023;3(2):28-31.
94. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. *AIDS: A Review. Newport International Journal of Public Health and Pharmacy (NIJPP)*. 2023;3(2):64-67.
95. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV Infection and Cardiovascular diseases: The obnoxious Duos. *Newport International Journal of Research in Medical Sciences (NIJRMS)*. 2023;3(2):95-99.
96. Onyenweaku FC, Amah HC, Obeagu EI, Nwandikor UU, Onwuasoanya UF. Prevalence of asymptomatic bacteriuria and its antibiotic susceptibility pattern in pregnant women attending private ante natal clinics in Umuahia Metropolitan. *Int J Curr Res Biol Med.* 2017;2(2):13-23.DOI: 10.22192/ijcrbm.2017.02.02.003
97. Okoroiwu IL, Chinedu-Madu JU, Obeagu EI, Vincent CC, Ochiabuto OM, Ibekwe AM, Amaechi CO, Agu CC, Anoh NV, Amadi NM. Evaluation of Iron Status, Haemoglobin and Protein Levels of Pregnant Women in Owerri Metropolis. *Journal of Pharmaceutical Research International*. 2021 Apr 29;33(27A):36-43.
98. Obeagu EI, Njar VE, Obeagu GU. Infertility: Prevalence and Consequences. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(7):43-50.
99. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM. Evaluation of levels of some inflammatory cytokines in preeclamptic women in owerri. *Journal of Pharmaceutical Research International*. 2021 Aug 25;33(42A):53-65.
100. Obeagu EI, Faduma MH, Uzoma G. Ectopic Pregnancy: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(4):40-4.DOI: 10.22192/ijcrps.2023.10.04.004
101. Obeagu EI, Gamade SM, Obeagu GU. The roles of Neutrophils in pregnancy. *Int. J. Curr. Res. Med. Sci.* 2023;9(5):31-5.DOI: 10.22192/ijcrms.2023.09.05.005
102. Eze R, Obeagu EI, Nwakulite A, Okoroiwu IL, Vincent CC, Okafor CJ, Chukwurah EF, Chijioko UO, Amaechi CO. Evaluation of Copper Status and Some Red Cell Parameters of Pregnant Women in Enugu State, South Eastern Nigeria. *Journal of Pharmaceutical Research International*. 2021 May 29;33(30A):67-71.
103. Obeagu EI, Obeagu GU. Molar Pregnancy: Update of prevalence and risk factors. *Int. J. Curr. Res. Med. Sci.* 2023;9(7):25-8.DOI: 10.22192/ijcrms.2023.09.07.005
104. Obeagu EI, Bunu UO. Factors that influence unmet need for family planning. *International Journal of Current Research in Biology and Medicine*. 2023;8(1):23-7.

105. Ibebuiké JE, Ojie CA, Nwokike GI, Obeagu EI, Nwosu DC, Nwanjo HU, Agu GC, Ezenwuba CO, Nwagu SA, Akujuobi AU. Barriers to utilization of maternal health services in southern senatorial district of Cross Rivers state, Nigeria. *International Journal of Advanced Multidisciplinary Research*. 2017;4(8):1-9. DOI: 10.22192/ijamr.2017.04.08.001
106. Emmanuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. *Asian Journal of Pregnancy and Childbirth*. 2023 Jul 29;6(1):203-11. <http://research.sdpublishers.net/id/eprint/2819/>.
107. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of coagulation parameters in malaria infected pregnant women in Imo state, Nigeria. *International Journal of Current Research in Medical Sciences*. 2018;4(9):41-9. DOI: 10.22192/ijcrms.2018.04.09.006
108. Obeagu EI, Obeagu GU. Postpartum haemorrhage among women delivering through spontaneous vaginal delivery: Prevalence and risk factors. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(8):22-6. DOI: 10.22192/ijcreps.2023.10.08.003
109. Obeagu E, Eze RI, Obeagu EI, Nnatuanya IN, Dara EC. ZINC LEVEL IN APPARENTLY PREGNANT WOMEN IN URBAN AREA. *Madonna University journal of Medicine and Health Sciences* ISSN: 2814-3035. 2022 Mar 2;2(1):134-48. <https://www.journal.madonnauniversity.edu.ng/index.php/medicine/article/view/40>.
110. Ogomaka IA, Obeagu EI. Malaria in Pregnancy Amidst Possession of Insecticide Treated Bed Nets (ITNs) in Orlu LGA of Imo State, Nigeria. *Journal of Pharmaceutical Research International*. 2021 Aug 25;33(41B):380-6.
111. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. SICKLE CELL ANAEMIA: A GESTATIONAL ENIGMA. migration. 2023;17:18.
112. Ifeanyi OE, Uzoma OG. A review on erythropoietin in pregnancy. *J. Gynecol. Womens Health*. 2018;8(3):1-4. [https://www.academia.edu/download/56538560/A\\_Review\\_on\\_Erythropoietin\\_in\\_Pregnancy.pdf](https://www.academia.edu/download/56538560/A_Review_on_Erythropoietin_in_Pregnancy.pdf).
113. Ifeanyi OE. A review on pregnancy and haematology. *Int. J. Curr. Res. Biol. Med.* 2018;3(5):26-8. DOI: 10.22192/ijcrbm.2018.03.05.006
114. Nwosu DC, Nwanjo HU, Obeagu EI, Ibebuiké JE, Ezeama MC, Ihekireh. Changes in liver enzymes and lipid profile of pregnant women with malaria in Owerri, Nigeria. *International Journal of Current Research and Academic Review*. 2015;3(5):376-83.
115. Ibebuiké JE, Ojie CA, Nwokike GI, Obeagu EI, Nwosu DC, Nwanjo HU, Agu GC, Ezenwuba CO, Nwagu SA, Akujuobi AU. Factors that influence women's utilization of primary health care services in Calabar Cross river state, Nigeria. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2017;4(7):28-33.
116. Ibebuiké JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research*, 2018; 1 (2):08-14. <https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf>.
117. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parameters in HIV patients before receiving treatment in Aba, Abia State, Nigeria. *Res J Pharma Biol Chem Sci*. 2014; 5:825-830.
118. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. *International Journal of Life Science, Biotechnology and Pharama Research*. 2014; 391:186-189.
119. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023; 3 (1): 7-12.
120. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. *International Journal of Innovative and Applied Research*. 2022;10(5):1-11.
121. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanjo CA, Nwanjo HU, Amadike JN, Eemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutase, vitamins C and E in HIV infected children in Umuahia, Abia state. *International Journal of Advanced Research in Biological Sciences*. 2015;2(11):268-271.
122. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. *Newport International Journal of Scientific and Experimental Sciences (NIJSES)*. 2023;3(2):56-59.
123. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. *Int. J. Curr. Res. Med. Sci.* 2018;4(2):104-108.

124. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. *Int. J. Adv. Res. Biol. Sci.* 2018;5(6):60-66.
125. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. *Arch Blood Transfus Disord.* 2018;1(2).
126. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci.* 2017;12(4):70-75.
127. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(52B):10-19.
128. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. *Medicine (Baltimore).* 2023;102(49): e36599. doi: 10.1097/MD.00000000000036599. PMID: 38065920; PMCID: PMC10713174.
129. Anyiam AF, Arinze-Anyiam OC, Ironi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. *Medicine (Baltimore).* 2023;102(47): e36342. doi: 10.1097/MD.00000000000036342. PMID: 38013335; PMCID: PMC10681551.
130. Echefu SN, Udosen JE, Akwivu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. *Medicine (Baltimore).* 2023;102(47): e35910. doi: 10.1097/MD.00000000000035910. PMID: 38013350; PMCID: PMC10681510.
131. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine (Baltimore).* 2023;102(46): e36166. doi: 10.1097/MD.00000000000036166. PMID: 37986340; PMCID: PMC10659731.
132. Alum EU, Obeagu EI, Ugwu OPC, Samson AO, Adepoju AO, Amusa MO. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. *Medicine (Baltimore).* 2023;102(41): e35673. doi: 10.1097/MD.00000000000035673. PMID: 37832059; PMCID: PMC10578718.
133. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. *Health Sci Rep.* 2023;6(8): e1450. doi: 10.1002/hsr.2.1450. PMID: 37520460; PMCID: PMC10375546.
134. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. *APPLIED SCIENCES (NIJBAS).* 2023;3(3).
135. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(11):14-25.
136. Eze R, Ezeah GA, Obeagu EI, Omeje C, Nwakulite A. Evaluation of iron status and some haematological parameters of pregnant women in Enugu, South Eastern Nigeria. *World Journal of Pharmaceutical and Medical Research.* 2021;7(5):251-4.
137. Elemchukwu Q, Obeagu EI, Ochei KC. Prevalence of Anaemia among Pregnant Women in Braithwaite Memorial Specialist Hospital (BMSH) Port Harcourt. *IOSR Journal of Pharmacy and Biological Sciences.* 2014;9(5):59-64.
138. Akandinda M, Obeagu EI, Katonera MT. Non Governmental Organizations and Women's Health Empowerment in Uganda: A Review. *Asian Research Journal of Gynaecology and Obstetrics.* 2022 Dec 14;8(3):12-6.
139. Vidya S, Sunil Kumar Shango Patience Emmanuel Jakheng, Emmanuel Ifeanyi Obeagu, Emmanuel William Jakheng, Onyekachi Splendid Uwakwe, Gloria Chizoba Eze, and Getrude Uzoma Obeagu (2022). Occurrence of Chlamydial Infection Based on Clinical Symptoms and Clinical History among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *International Journal of Research and Reports in Gynaecology.*;5(3):98-105.
140. Gamde MS, Obeagu EI. IRON DEFICIENCY ANAEMIA: ENEMICAL TO PREGNANCY. *European Journal of Biomedical.* 2023;10(9):272-5. [links/64f63358827074313ffaae7b/IRON-DEFICIENCY-ANAEMIA-ENEMICAL-TO-PREGNANCY.pdf](https://doi.org/10.1002/links/64f63358827074313ffaae7b/IRON-DEFICIENCY-ANAEMIA-ENEMICAL-TO-PREGNANCY.pdf).
141. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM. Evaluation of levels of some inflammatory cytokines in preeclamptic women in owerri. *Journal of Pharmaceutical Research International.* 2021 Aug 25;33(42A):53-65.

142. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM. Studies of Some Haemostatic Variables in Preeclamptic Women in Owerri, Imo State, Nigeria. *Journal of Pharmaceutical Research International*. 2021 Aug 30;33(42B):39-48.
143. Obeagu EI, Obeagu GU. Postpartum haemorrhage among women delivering through spontaneous vaginal delivery: Prevalence and risk factors. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(8):22-6.
144. Obeagu EI, Obeagu GU. Sick Cell Anaemia in Pregnancy: A Review. *International Research in Medical and Health Sciences*. 2023 Jun 10;6(2):10-3.
145. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. *Int. J. Adv. Multidiscip. Res.* 2023;10(10):56-62.
146. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sick Cell Anaemia. *Newport International Journal of Scientific and Experimental Sciences (NIJSES)*. 2023;3(2):56-9.
147. Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, Uti DE. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. *International Journal of Innovative and Applied Research*. 2023;11(10):01-6.
148. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. *Elite Journal of Public Health*. 2024;2(1):8-22.
149. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. *Elite Journal of Immunology*. 2024;2(1):14-33.
150. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. *Medicine*. 2024;103(9):e37354.
151. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. *Elite Journal of Immunology*. 2024;2(1):1-3.
152. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. *Elite Journal of Immunology*. 2024;2(1):34-46.
153. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):46-58.
154. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. *Elite Journal of Medicine*. 2024;2(1):35-46.
155. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. *Journal home page: <http://www.journalijiar.com>;12(01)*.
156. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. *Elite Journal of HIV*. 2024;2(1):65-78.
157. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. *Journal home page: <http://www.journalijiar.com>;12(01)*.
158. Obeagu EI AA, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. *Elite Journal of HIV*. 2024;2(1):31-50.
159. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. *Elite Journal of HIV*. 2024;2(1):1-5.
160. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci.* 2024;10(1):25-36.
161. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. *Sciences*. 2024;4(1):32-7.
162. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. *Sciences*. 2024;4(1):38-44.
163. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. *Elite Journal of Health Science*. 2024;2(1):33-42.
164. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. *Elite Journal of Haematology*. 2024;2(1):26-41.
165. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. *Elite Journal of Medicine*. 2024;2(2):104-15.
166. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*. 2024;2(1):47-64.
167. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. *Elite Journal of HIV*. 2024;2(2):1-7.

168. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*. 2024;2(1):52-61.
169. Obeagu EI, Obeagu GU. Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. *Elite Journal of Public Health*. 2024;2(1):22-34.
170. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(1):21-31.
171. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. *Journal home page: <http://www.journalijar.com>;12(01)*.
172. Acton QA. *Allergies: New Insights for the Healthcare Professional: 2013 Edition*. ScholarlyEditions; 2013.